Combining 21 trials evaluating lipid outcomes , fish oil consumption result ed in a summary net change in triglycerides of -27 ( 95 % CI -33 , -20)mg/dL , in HDL cholesterol of + 1.6 ( 95 % CI + 0.8 , + 2.3)mg/dL , and in LDL cholesterol of + 6 ( 95 % CI + 3 , + 8)mg/dL. There was no effect of fish oil on total cholesterol .
Across studies , higher fish oil dose and higher baseline levels were associated with greater reductions in serum triglycerides .
The evidence supports a dose-dependent beneficial effect of fish oil on serum triglycerides , particularly among people with more elevated levels .
Fish oil consumption also modestly improves HDL cholesterol , increases LDL cholesterol levels , but does not appear to adversely affect glucose homeostasis .
The evidence regarding the effects of omega-3 fatty acids on hs-CRP is inconclusive , as are data on ALA
Greater fish oil consumption has been associated with reduced CVD risk , although the mechanisms are unclear .
Plant- source oil omega-3 fatty acids ( ALA ) have also been studied regarding their cardiovascular effect .
Effects of a fish oil supplement on blood pressure and serum lipids in patients treated for coronary artery disease.
OBJECTIVE The purpose of this study was to evaluate the effects of a concentrate of fish oil on blood pressure and serum lipids in patients treated for coronary artery disease . DESIGN One hundred and twenty-five patients were r and omly assigned to receive 15 g/day MaxEPA ( 4.5 g eicosapentaenoic and docosahexaenoic acids ) or olive oil .  Blood pressure and serum lipids were measured at enrollment and six months thereafter . MAIN RESULTS As an important proportion of antihypertensive or antianginal drug users stopped their usual medication during the trial , blood pressure increased in both groups . The increase in systolic blood pressure was less in the fish oil group than in the control group ( P = 0.002 ) . Serum triglyceride levels decreased markedly in the fish oil group while they remained constant in the control group ( P = 0.0001 ) . Fish oil supplementation had no effect on total cholesterol and only marginal independent influence on high density lipoprotein and low density lipoprotein cholesterol levels . CONCLUSIONS In conclusion , fish oil supplementation has a beneficial effect on blood pressure and serum triglycerides in patients treated for coronary artery disease
Combining 21 trials evaluating lipid outcomes , fish oil consumption result ed in a summary net change in triglycerides of -27 ( 95 % CI -33 , -20)mg/dL , in HDL cholesterol of + 1.6 ( 95 % CI + 0.8 , + 2.3)mg/dL , and in LDL cholesterol of + 6 ( 95 % CI + 3 , + 8)mg/dL. There was no effect of fish oil on total cholesterol .
Across studies , higher fish oil dose and higher baseline levels were associated with greater reductions in serum triglycerides .
The evidence supports a dose-dependent beneficial effect of fish oil on serum triglycerides , particularly among people with more elevated levels .
Fish oil consumption also modestly improves HDL cholesterol , increases LDL cholesterol levels , but does not appear to adversely affect glucose homeostasis .
The evidence regarding the effects of omega-3 fatty acids on hs-CRP is inconclusive , as are data on ALA
Greater fish oil consumption has been associated with reduced CVD risk , although the mechanisms are unclear .
Plant- source oil omega-3 fatty acids ( ALA ) have also been studied regarding their cardiovascular effect .